NDT Advance Access originally published online on November 24, 2006
Nephrology Dialysis Transplantation 2007 22(2):522-528; doi:10.1093/ndt/gfl620
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Efficacy of percutaneous ethanol injection therapy (PEIT) is related to the number of parathyroid glands in haemodialysis patients with secondary hyperparathyroidism
1Division of Nephrology, Department of Internal medicine, Showa University Fujigaoka Hospital, Yokohama 227-8501, Japan, 2Department of Internal Medicine, Tokai University School of Medicine, Isehara 259-1193, Japan and 3Department of Nephroendocrinology, Kojinkai Central Hospital, Sendai, 983-0852, Japan
Correspondence and offprint requests to: Fumihiko Koiwa, MD, PhD, Division of Nephrology, Department of Internal Medicine, Showa University Fujigaoka Hospital, 1-30 Fujigaoka, Aoba-ku, Yokohama 227–8501, Japan. Email: f-koiwa{at}showa-university-fujigaoka.gr.jp
 |
Abstract |
|---|
Background. Percutaneous ethanol injection therapy (PEIT) is used for advanced secondary hyperparathyroidism. We investigated the efficacy, remission period and risk of relapse to determine the effect of the number of hyperplastic glands and other factors on the therapeutic effect of PEIT.
Methods. We studied 321 patients divided into two groups: effective [serum corrected calcium (cCa) level 
10.5 mg/dl and serum intact parathyroid hormone (iPTH) level 250 pg/ml], and ineffective (failed to achieve the target levels). Advanced hyperplasia was defined as an estimated volume 
0.5 cm3 on ultrasonography.
Results. PEIT was effective in 201 patients (62.6%), in whom serum iPTH levels dropped from 603±292 to 183±62 pg/ml (ng/l) and serum cCa levels from 10.7±0.8 to 10.1±0.5 mg/dl. Univariate analysis identified age, the number of hyperplastic glands and iPTH level as factors related to the efficacy of PEIT. The odds ratio for success vs failure by multivariate analysis was 0.55 times for the number of hyperplastic glands 0.5 cm3 (2 vs 0,1) and 0.29 times for iPTH (500 vs <500 pg/ml). Using the Kaplan–Meier method, the number of hyperplastic glands 0.5 cm3 (2 vs 0,1) was a factor affecting the remission period, with a remission significantly longer seen in the group with one hyperplastic gland (P=0.0025).
Conclusions. Superior results in efficacy rate, remission period and risk of relapse are obtained when PEIT is restricted to patients with one hyperplastic gland 0.5 cm3.
Keywords: chronic renal failure; parathyroid hyperplasia; percutaneous ethanol injection therapy (PEIT); secondary hyperparathyroidism
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  C. Cappelli, G. Pelizzari, I. Pirola, E. Gandossi, E. De Martino, A. Delbarba, B. Agosti, E. Agabiti Rosei, and M. Castellano Modified percutaneous ethanol injection of parathyroid adenoma in primary hyperparathyroidism QJM, May 22, 2008; (2008) hcn062v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Fukagawa, T. Akizawa, and for the Japanese Society for Parathyroid Intervent Control of severe hyperparathyroidism in dialysis patients with nodular hyperplasia NDT Plus, January 1, 2008; 1(suppl_3): iii1 - iii1. [Full Text] [PDF]
|
|
|
|
|
|
S. Goto, H. Komaba, and M. Fukagawa Pathophysiology of parathyroid hyperplasia in chronic kidney disease: preclinical and clinical basis for parathyroid intervention NDT Plus, January 1, 2008; 1(suppl_3): iii2 - iii8. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Ogata, M. Mizobuchi, F. Koiwa, E. Kinugasa, and T. Akizawa Clinical significance of parathyroid intervention on CKD-MBD management NDT Plus, January 1, 2008; 1(suppl_3): iii9 - iii13. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Koiwa, T. Hasegawa, R. Tanaka, and T. Kakuta Indication and efficacy of PEIT in the management of secondary hyperparathyroidism NDT Plus, January 1, 2008; 1(suppl_3): iii14 - iii17. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Kakuta, M. Fukagawa, M. Kitaoka, F. Koiwa, N. Onoda, Y. Tominaga, T. Akizawa, K. Kurokawa, and for the Japanese Society for Parathyroid Intervent Percutaneous ethanol injection therapy for advanced renal hyperparathyroidism in Japan: 2004 survey by the Japanese Society for Parathyroid Intervention NDT Plus, January 1, 2008; 1(suppl_3): iii21 - iii25. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Tanaka, T. Kakuta, F. Koiwa, M. Fukagawa, and A. Saito Long-term prognosis of parathyroid function in chronic dialysis patients after PEIT--a single-centre trial NDT Plus, January 1, 2008; 1(suppl_3): iii29 - iii34. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Tominaga Current status of parathyroidectomy for secondary hyperparathyroidism in Japan NDT Plus, January 1, 2008; 1(suppl_3): iii35 - iii38. [Full Text] [PDF]
|
|
|
|
|
|
M. Nakamura, Y. Marui, Y. Ubara, S. Nakanishi, F. Takemoto, K. Takaichi, and S. Tomikawa Effects of percutaneous ethanol injection therapy on subsequent surgical parathyroidectomy NDT Plus, January 1, 2008; 1(suppl_3): iii39 - iii41. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Tanaka and M. Fukagawa Medical management after parathyroid intervention NDT Plus, January 1, 2008; 1(suppl_3): iii18 - iii20. [Abstract] [Full Text] [PDF]
|
|